PROMOMED’s Velgia®: a novel Russian semaglutide product is already available in pharmacies, and its treatment course is by one third more affordable compared to competitor brands

PROMOMED, a top-level innovative biopharmaceutical company, one of the largest Russian pharmaceutical manufacturers, announces the launch of Velgia® (INN semaglutide), a next generation Russian-made medicine for the treatment for overweight and obesity. The first batches of the drug are already available in Russian pharmacies.

Overweight and obese patients will mostly benefit from this novel medicine. It significantly reduces weight, also addressing the disorders that eventually lead up to cardiovascular diseases and cancer - the main causes of mortality in Russia.

Velgia® is available in five dosage strengths, each containing meticulously selected concentrations to ensure optimal weight loss results. For comfortable use, the Company has improved the pre-filled pen design by providing a convenient push-button mechanism of drug administration – requiring literally just one easy press for dosing, which ensures simplicity and ease of use for patients. One pre-filled pen contains 4 equal doses and is designed for one month of use. In addition, the kit includes needles for subcutaneous administration.

Thanks to technology, innovative solutions, specially designed pre-filled pen and local manufacturing, the cost of the compared to competitor brands is one third less, which makes it as affordable as possible for patients and reduces the cost of the treatment course.

“One of the Company's commitments is to increase the availability of quality medicines for Russian residents. Such initiatives are not only instrumental for health protection, but also dramatically improve the quality of life. The launch of the new product sets an example of full-cycle import substitution. Everything from the substance to the convenient pre-filled pens at our own facilities, is produced at our own manufacturing facilities”, commented Ilya Bardin-Denisov, PROMOMED DM LLC CEO.

Addressing the journalists earlier, Mikhail Murashko, the Minister of Health of the Russian Federation, noted that about 40 million residents of Russia are overweight and therefore at higher risk of developing various diseases.*
Velgia® heralds a new era of effective treatment for obesity in Russia.